Company

Centivax

Biotech company developing universal immunity technologies including a universal flu vaccine and a broad-spectrum antivenom derived from antibodies of Tim Friede, who self-immunized against 16 deadly snake species

Healthcare & Biotech

People

Jacob Glanvilleceo

Funding History

Jul 9, 2025Series A

Centivax closed a Series A raising $45M, bringing total capital raised to nearly $100M. The company plans to begin first-in-human trials within eight months. Prior funding included approximately $50M, half non-dilutive from Gates Foundation, CEPI, the US Navy, Army, and Naval Medical Research Command.

45M

Investors

NFX

News

Interviews (1)

Centivax CEO Jacob Glanville on a universal flu vaccine targeting 80-95% efficacy and a single antivenom for all snakes
8 Jul 2025